Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Kinetic properties of “dual” orexin receptor antagonists at OX1R and OX2R orexin receptors
Gabrielle E. Callander, Morenike Olorunda, Dominique Monna, et al.
Frontiers in Neuroscience (2013) Vol. 7
Open Access | Times Cited: 35

Showing 1-25 of 35 citing articles:

Hypocretins (orexins): The ultimate translational neuropeptides
Laura H. Jacobson, Daniël Hoyer, Luı́s de Lecea
Journal of Internal Medicine (2022) Vol. 291, Iss. 5, pp. 533-556
Closed Access | Times Cited: 71
The Discovery of Suvorexant, the First Orexin Receptor Drug for Insomnia
Paul J. Coleman, Anthony L. Gotter, W. Joseph Herring, et al.
The Annual Review of Pharmacology and Toxicology (2016) Vol. 57, Iss. 1, pp. 509-533
Closed Access | Times Cited: 114
Discovery and first-time disclosure of CVN766, an exquisitely selective orexin 1 receptor antagonist
Angela Glen, Roland W. Bürli, David G. Livermore, et al.
Bioorganic & Medicinal Chemistry Letters (2024) Vol. 100, pp. 129629-129629
Open Access | Times Cited: 8
Recent trends in orexin research—2010 to 2015
Christoph Boss, Catherine Roch
Bioorganic & Medicinal Chemistry Letters (2015) Vol. 25, Iss. 15, pp. 2875-2887
Closed Access | Times Cited: 74
Orexin 2 Receptor Antagonism is Sufficient to Promote NREM and REM Sleep from Mouse to Man
Anthony L. Gotter, Mark S. Forman, C. Meacham Harrell, et al.
Scientific Reports (2016) Vol. 6, Iss. 1
Open Access | Times Cited: 72
Suvorexant: The first orexin receptor antagonist to treat insomnia
Ashok Kumar Dubey, Shailendra Handu, Pramod Kumari Mediratta
Journal of Pharmacology and Pharmacotherapeutics (2015) Vol. 6, Iss. 2, pp. 118-121
Open Access | Times Cited: 64
Orexin/Hypocretin Based Pharmacotherapies for the Treatment of Addiction: DORA or SORA?
Shaun Yon‐Seng Khoo, Robyn M. Brown
CNS Drugs (2014) Vol. 28, Iss. 8, pp. 713-730
Open Access | Times Cited: 58
Suvorexant for the treatment of insomnia
Laura H. Jacobson, Gabrielle E. Callander, Daniël Hoyer
Expert Review of Clinical Pharmacology (2014) Vol. 7, Iss. 6, pp. 711-730
Closed Access | Times Cited: 52
Orexin Signaling: A Complex, Multifaceted Process
Natasha C. Dale, Daniël Hoyer, Laura H. Jacobson, et al.
Frontiers in Cellular Neuroscience (2022) Vol. 16
Open Access | Times Cited: 26
The Quest for the Best Dual Orexin Receptor Antagonist (Daridorexant) for the Treatment of Insomnia Disorders
Christoph Boss, John Gatfield, Christine Brotschi, et al.
ChemMedChem (2020) Vol. 15, Iss. 23, pp. 2286-2305
Closed Access | Times Cited: 37
Distinct effects of IPSU and suvorexant on mouse sleep architecture
Daniël Hoyer, Thomas Dürst, Markus Fendt, et al.
Frontiers in Neuroscience (2013) Vol. 7
Open Access | Times Cited: 39
Orexin OX2 Receptor Antagonists as Sleep Aids
Laura H. Jacobson, Sui Chen, Sanjida Mir, et al.
Current topics in behavioral neurosciences (2016), pp. 105-136
Open Access | Times Cited: 35
Clinical Pharmacology of Other Drugs Used as Hypnotics
Daniel J. Buysse, Shachi Tyagi
Elsevier eBooks (2016), pp. 432-445.e7
Closed Access | Times Cited: 34
Hypnotics with novel modes of action
Daniël Hoyer, Andrew G. Allen, Laura H. Jacobson
British Journal of Clinical Pharmacology (2019) Vol. 86, Iss. 2, pp. 244-249
Open Access | Times Cited: 33
Orexin A attenuates palmitic acid-induced hypothalamic cell death
Cayla M. Duffy, Joshua P. Nixon, Tammy A. Butterick
Molecular and Cellular Neuroscience (2016) Vol. 75, pp. 93-100
Open Access | Times Cited: 27
Manipulation of rapid eye movement sleep via orexin and GABAA receptor modulators differentially affects fear extinction in mice: effect of stable versus disrupted circadian rhythm
Jacob Clark, Heather Daykin, Jeremy A. Metha, et al.
SLEEP (2021) Vol. 44, Iss. 9
Open Access | Times Cited: 17
Synthesis of [11C]MK-1064 as a new PET radioligand for imaging of orexin-2 receptor
Mingzhang Gao, Min Wang, Qi-Huang Zheng
Bioorganic & Medicinal Chemistry Letters (2016) Vol. 26, Iss. 15, pp. 3694-3699
Open Access | Times Cited: 19
Is suvorexant a better choice than alternative hypnotics?
Daniel F. Kripke
F1000Research (2015) Vol. 4, pp. 456-456
Open Access | Times Cited: 18
A New Positron Emission Tomography Probe for Orexin Receptors Neuroimaging
Ping Bai, Sha Bai, Michael S. Placzek, et al.
Molecules (2020) Vol. 25, Iss. 5, pp. 1018-1018
Open Access | Times Cited: 15
The distribution of hypocretin/orexin receptor mRNA in the mouse and human brain
Sanjida Mir, Ryan J. Keenan, Romke Bron, et al.
Medicine in Drug Discovery (2024) Vol. 24, pp. 100202-100202
Open Access | Times Cited: 1
On the kinetic features of orexin receptor antagonists at orexin receptors, transduction systems and receptor binding
Daniël Hoyer, Laura H. Jacobson
Medicine in Drug Discovery (2024) Vol. 22, pp. 100190-100190
Open Access | Times Cited: 1
International Union of Basic and Clinical Pharmacology CXIV: Orexin Receptor Function, Nomenclature and Pharmacology
Jyrki P. Kukkonen, Laura H. Jacobson, Daniël Hoyer, et al.
Pharmacological Reviews (2024), pp. PHARMREV-000953
Open Access | Times Cited: 1
The risks of using unapproved gene symbols
Bryony Braschi, Ruth L. Seal, Susan Tweedie, et al.
The American Journal of Human Genetics (2021) Vol. 108, Iss. 10, pp. 1813-1816
Open Access | Times Cited: 8
Clinical Spectrum and Trajectory of Innovative Therapeutic Interventions for Insomnia: A Perspective
Yun-Jo Lo, Viraj Krishna Mishra, Hung-Yao Lo, et al.
Aging and Disease (2022)
Open Access | Times Cited: 4
Page 1 - Next Page

Scroll to top